
Evolus (EOLS) Stock Forecast & Price Target
Evolus (EOLS) Analyst Ratings
Bulls say
Evolus Inc reported a significant 29.4% year-over-year increase in total net revenue, reaching $78.9 million in the fourth quarter of 2023, primarily driven by a surge in Jeuveau sales alongside the acquisition of approximately 830 new accounts. The company’s adjusted gross margin remained strong at 67.5%, indicating effective cost management and stable profitability in the aesthetics market. Additionally, the anticipated launch of the Evolysse fillers is expected to enhance revenue contributions significantly, projected at 8-10% of total revenue for fiscal year 2025, which bolsters the company’s growth outlook amidst a favorable market trend emphasizing aesthetic treatments among younger consumers.
Bears say
Evolus Inc reported a GAAP net loss of $6.8 million for the fourth quarter of 2023, translating to a loss per share of $0.11, which exceeded the company's own estimate but fell short of the market consensus. The company faces significant operational challenges, including reliance on third-party suppliers for manufacturing Jeuveau, posing risks related to supply chain disruptions and competitive pressures from larger firms. Additionally, increasing operating expenses associated with the marketing of Jeuveau and the development of extra-strength formulations heighten financing risks that could impact future financial performance.
This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.
Evolus (EOLS) Analyst Forecast & Price Prediction
Start investing in Evolus (EOLS)
Order type
Buy in
Order amount
Est. shares
0 shares